ࡱ>  +bjbjVV HX<<X"~ ~ 8 <I|5.x5z5z5z5z5z5z579z5tttz55tRx5tx5=0'3F2d26d55052~?:H?:l33?:,38Z @M4z5z55tttt?:~ :  SCOPE: All Company-affiliated hospitals performing and/or billing laboratory services. Specifically, the following departments: Business Office Nursing Admitting/Registration Laboratory Administration Case Management Revenue Integrity Shared Services Centers Health Information Management Reimbursement PURPOSE: To establish guidelines for billing Organ and Disease panels in accordance with Medicare, Medicaid, and other federally-funded payer requirements. POLICY: Organ and Disease panels and component tests billed to a federally-funded program must be based on a written order and be medically necessary. Only the Centers for Medicare and Medicaid Services (CMS)-approved Organ and Disease panels will be billed at the panel level to Medicare, Medicaid and other federally-funded payers, unless the payer has provided written documentation regarding the acceptance of other American Medical Association defined Organ and Disease panels. Chemistry components will be bundled to the panel level when all of the tests in the panel are ordered and performed. Repeated laboratory tests, including repeated components of panels, may be billed when the tests are medically necessary, which is indicated by reporting modifier 91. Modifier 91 may only be reported when in the course of treating a patient, it is necessary to repeat the same laboratory test on the same day to obtain subsequent test results. This modifier may not be reported when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. This modifier may not be used when other code(s) describe a series of test results (e.g., glucose tolerance tests, evocative/suppression testing). If a payer does not recognize or accept modifier 91 and the payer has not provided you with their specific billing guidance for repeated laboratory tests, these tests may not be billed. If a CPT code is a component of a CMS-approved Organ and Disease panel, a subsequent test performed on a different specimen type may be billed when medically necessary, which is indicated by reporting modifier 59. If a payer does not recognize or accept modifier 59 and the payer has not provided you with their specific billing guidance for repeated laboratory tests, these tests may not be billed. CMS has established Medically Unlikely Edits (MUE) and National Correct Coding Initiative (NCCI) edits. MUEs may trigger when units of service on a given claim line item exceed the established limit for that HCPCS code. NCCI edits may trigger when there are restrictions on code combinations reported on a single date of service. MUEs and/or NCCI edits may supersede information within this policy. PROCEDURE: The following steps must be performed when billing Organ and Disease panels to Medicare, Medicaid, and other federally-funded programs. IMPLEMENTATION Assign CPT/HCPCS codes and revenue codes for each panel and panel component test in accordance with the Company Standard Laboratory Chargemaster. Set-up the Laboratory and Order Entry dictionaries or masterfiles to enable the ordering and billing of panels. 80047 Basic Metabolic Panel (Calcium, Ionized) National Limit Amount $11.91 Revenue Code 301 Calcium, ionized (82330) Carbon dioxide (82374) Chloride (82435) Creatinine (82565) Glucose (82947) Potassium (84132) Sodium (84295) Urea Nitrogen (BUN) (84520) 80048 Basic Metabolic Panel (Calcium, Total) National Limit Amount $11.91 Revenue Code 301 Calcium, total (82310) Carbon dioxide (82374) Chloride (82435) Creatinine (82565) Glucose (82947) Potassium (84132) Sodium (84295) Urea nitrogen (BUN) (84520) 80051 Electrolyte Panel National Limit Amount $ 9.87 Revenue Code 301 Carbon dioxide (82374) Chloride (82435) Potassium (84132) Sodium (84295) 80053 Comprehensive Metabolic Panel National Limit Amount $14.87 Revenue Code 301 Albumin (82040) Bilirubin, total (82247) Calcium, total (82310) Carbon dioxide (82374) Chloride (82435) Creatinine (82565) Glucose (82947) Phosphatase, alkaline (84075) Potassium (84132) Protein, total (84155) Sodium (84295) Transferase, alanine amino (ALT),(SGPT) (84460) Transferase, aspartate amino (AST) (SGOT) (84450) Urea nitrogen (BUN) (84520) 80061 Lipid Panel National Limit Amount - None Revenue Code 301 State Range: Low: $11.83 High: $14.87 Cholesterol, serum, total (82465) Lipoprotein, direct measurement, high density cholesterol (HDL cholesterol) (83718) Triglycerides (84478) 80069 Renal Function Panel National Limit Amount $12.22 Revenue Code 301 Albumin (82040) Calcium; total (82310) Carbon dioxide (82374) Chloride (82435) Creatinine (82565) Glucose (82947) Phosphorus inorganic (phosphate) (84100) Potassium (84132) Sodium (84295) Urea nitrogen (BUN) (84520) 80074 Acute Hepatitis Panel National Limit Amount None Revenue Code 300 State Range: Low: $57.92 High: $67.01 Hepatitis A antibody (HAAb), IgM antibody (86709) Hepatitis B core antibody (HBcAb), IgM antibody (86705) Hepatitis B surface antigen (HBsAg) (87340) Hepatitis C antibody (86803) 80076 Hepatic Function Panel National Limit Amount $11.49 Revenue Code 301 Albumin (82040) Bilirubin; total (82247) Bilirubin; direct (82248) Phosphatase, alkaline (84075) Protein, total (84155) Transferase, aspartate amino (AST) (SGOT) (84450) Transferase, alanine amino (ALT) (SGPT) (84460) Business Office or Service Center personnel must verify that edits are present in the electronic billing system which: Bundle individual component tests to the most comprehensive panel level as defined in this procedure. Compare individual component tests within each panel to any component tests not billed as part of a panel and identify repeated tests. Compare individual component tests of multiple panels and identify duplicate components. Laboratory and Business Office/Service Center personnel must educate all staff associates responsible for ordering, charging, or billing laboratory services regarding the requirements of this policy. Monitoring activities must be completed in accordance with the Billing Monitoring Policy, REGS.GEN.001. DAILY It is recommended but not required that laboratory personnel review daily charge reports (e.g.,Ancillary Charge Report, NPR charge reports, etc.) to verify compliance with this policy as follows: Bundle individual component tests to the most comprehensive panel level as defined in this procedure. Compare individual component tests within each panel to any component tests not billed as part of a panel and identify repeated tests. Compare individual component tests of multiple panels and edit for duplicate components. Service Center or Business Office personnel must review electronic billing edit/error reports daily and perform the following: Bundle chemistry components to the appropriate comprehensive panel. Identify the presence of repeated panels and component tests and determine if documentation is present to support medical necessity. Append the appropriate modifier (59 or 91) to repeated tests or panels which are medically necessary. Eliminate repeated tests or panels which are not medically necessary. Modify number of units and related charges in the electronic billing vendor system to reflect the appropriate charge for the panel being billed. The Facility Ethics and Compliance Committee is responsible for implementation of this policy within the facility. REFERENCES: Medicare Claims Processing Manual, Chapter 16, Section 90 AMA CPT Assistant, Summer 1993 Pages: 14-15 AMA CPT Assistant, January 1998 Pages: 7-8 American Medical Association Physicians Current Procedural Terminology CPT Current Year Clinical Lab Fee Schedule CMS website - National Correct Coding Initiative edits       DEPARTMENT: Regulatory Compliance SupportPOLICY DESCRIPTION: Organ and Disease PanelsPAGE:  PAGE 1 of 5REPLACES POLICY DATED: 1/16/98, 3/1/99, 4/1/00, 8/1/02, 1/1/02, 2/15/03, 8/1/03 (GOS.LAB.004); 3/6/06;1/1/08; 7/1/09, 5/15/10EFFECTIVE DATE: January 1, 2011REFERENCE NUMBER: REGS.LAB.004 APPROVED BY: Ethics and Compliance Policy Committee 12/2011    9 : ; E w { (  *.Y릞랖hYKBB*CJaJphhF>CJaJh]WCJaJhYKBB*CJph hYKB6CJ hWpCJ hMzCJ h]WCJ h@OCJhYKBh .hewCJh .hYKBCJ hOCJ hYKBCJ hYKB5CJ hj5CJ4 * 9 : 0$If^`0 0$If^`0gdO $IfgdO $IfgdO$If $If^`gd^ : ; 8 9 7`kds$$Ifl     )'0     '44 laE$If`kd$$Ifl     )'0     '44 laE9 Z[zq $Ifgd5 & F$If`kd$$Ifl     )'0     '44 laE $IfgdLl;$If $7$8$H$If Y[ ľиxxmړfښbh5 hb5CJhhYKBCJaJhh5B*CJaJphhh~B*CJaJph h55CJ h@O5CJ hx`5CJh5h55CJ h5CJ hWpCJ h{CJhYKB5B*CJph hYKBCJhYKB hYKB5CJh &hyCJaJ hzp CJ hyCJh &CJaJ$(9L\n}#n$If$If]^$If]^ $If^gd $If^gd*+>BRST!&678GH{Zm$8=GL%&o猷 h4Z5CJhh~h@Ohx`hYKBCJ h@OCJ hh~5CJ h4ZCJhYKBhYKBB*phhYKBB*CJphhYKB5B*CJph h55CJ h@O5CJ hYKB5CJ hh~CJ hYKBCJ hY+CJ7CT'80GV $$Ifa$ *$If]^$If]^ n$If]^$If]^8<YZ#Mq$If$If  n$If$If]^ $If^gdx` $If^$If]^=lmM=no 4 j $If $$Ifa$  n$If $If^$If$If]^$Ifo  4 K ! !!p!q!""""""#########$ $$P$T$U$V$&&&''''''((ۼ۶۶۰۩۩ۢۜېېۊ hLl;CJ hCLCJ h:NCJ hCJ hYKB6CJ hYKB>*CJ h{oCJ hI:CJ hvCJhYKBB*CJphhYKBB*ph *hYKBCJ hYKBCJhYKBB*phhh~hYKB h@O5CJ hYKB5CJ4 q!!`"""#####$!%%&& & F0$If^`0 & F$If & F$Ifh$If^h`$If & F$If$If^` & F $If & F$If&&&O''(() ) $If^$If & F $If^gdk & F $If^gdCL & F $If^gdCL & F V$If^V`(())) ) )))P)Q)d)o)})~)))))))**+*,*N*T*U*V*X*Y*[*\*^*_*a*b*d*s*t*v*{j{ j?h.Ph08UmHnHuhLl;hxXjhxXU hYKBaJhh aJhh};AaJhh4ZaJhhx`aJhhYKBB*ph hhhhME5\aJhhMEaJhh{ohYKB hYKB5CJ hYKBCJhkhN95CJ( ) )))Q)~)))*U*V*~u $Ifgd & F$Ifgdx` & F$Ifgd$If`kdY$$Ifl     )'0     '44 laE V*W*X*Z*[*]*^*`*a*c*d*u*v*** 4$If^`$If`kd$$Ifl     )'0     '44 laEv***************T+\+e+f+g+w+y+z+++++++++++++++++·~uqmimehxXhuhN9hK<hK<hK<CJ hK<CJ hK<5CJhLl;5CJ\ h CJ h CJ\ hkCJ\ hLl;CJ\h3CJaJh ZThyCJaJh ZThLl;CJaJhR0JCJmHnHuhLl;0JCJjh00JCJUhLl; hLl;CJ hLl;5CJ&***f+ug $If` h$If^h`xkdW$$Ifl    0)H0    '44 la<f+g+++o $If^gdu $Ifgduvkd$$Ifl    0)H0    '44 la<+++x $If^gdbvkdw$$Ifl    0)H0    '44 la<++++++++fkd$$Ifl    )'0    '44 la<ytN9++hYKBF00P&P1h:p / =!`"#$% Dpq$$IfE!vh5'#v':V l0     '5'aEq$$IfE!vh5'#v':V l0     '5'aEq$$IfE!vh5'#v':V l0     '5'aEq$$IfE!vh5'#v':V l0     '5'aEq$$IfE!vh5'#v':V l0     '5'aEDd  ~A?HCA-blue2003Picture 1HCA-blue2003R"W_Y $VwFW_Y $VwJFIF,,C     C   0" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?;EcQ?X?vrJ+i;<KO/oGg(;EcQ}(X?vriV<Ҋ?i;KO/oGg(;EcQ}(X?vriV<Ҋ?i;KO/oGg(;EcQ}(X?vriV<Ҋ?i;KO/oGg(;EcQ}(#Viw_ri$H*""K3d1^_ϧ'%'K".,;pdAEWuQ@Q@yD|*5;;Q BW#ttiVR k,۫de(g(&"H;EcQ?X?vrJ+X?vriV<Ҋ?i;KO/oGg(;EcQ}(X?vriV<Ҋ?i;KO/oGg(;EcQ}(X?vriV<Ҋ?i;KO/oGg(;EcQ}(X?vriV<Ҋ?i;KOZ(=(((((((_ ;EMS>&#qEo& $Lbp9ϿWmGR~xK ׼A":DC2ڦcIB I*2^> +qӿC Og鞩YeޣaB7wR,qC)gwv *Nw$xj$; 4lHYpUV3C~7V㿎j9=nbϑ*L8v\5} *δa?-SėX5ksI_)qXm V+);W{[׉>jR>BXzE춒E*Jqx:r֌/\hȟ_VL>:,~"[>luW|10_;_o4+ؾ ȏE_dDaG,cGbC،Q= xu6gДQEyHWɿQ_k]~Q;UK񆽨pK5h!]1󃕕o|6ojph K3UAff ~_u3Ʊmb/}d6zjNGcl…bCH0U݁X?cVqݟA| )bm?CӮ5;T411 p =<~:uPCkzƧsĒ+HBI8I(suP]L*(B(g5E吏L:iMcwQXȱ{N@A/g{gKtM]iZWP]Cč3,YXg>y?=\Mz+OX((((((((_{_u8'Þ$"[wi6rA 1q'o/ >ZsD1;vxO+EUpޞ"/m|N 鶗ly<#XdXe[o#HUhPq-o/*OYh7~}O1yݒ2H+0 ?f ~}_Ovuc >9$ ݣ+  |#a=2/$@<#`dUU.c,Tcv|Sm4|uEV>j,e[dG I_ ?a/ ӾiW3$ڔAK)$Er l#8${6;[Z~GL/x_4 x{J֟,KM"+HRK@,B3(wf[DQE!Q@Q@axGxWtjQ]Ē$@`q1nM6Кx mN+Gᦕmj?S?Og?ţGڼֱMi}>H?-ȡв4w7 z |]a2ѐL <A" +Ve??,xڣ:5م.0m̉}]O eقEzMW<|Fػ(h ( ( (O xoQtGfcgoS͚W nbrIg)6߆*Xt7!~c- y7ݎ0΀Uw +/?HGRԾ'|?:D ]>cIBC**+_fٟ߳S@횝umrhϨN#'dk $ 'fwo_5''>W_+՟/# ifo ]Ba85 iH]D$bʸ`$>x .oszy.}&WB%IU82Q^LEj삊(s@((((([-5}zl?|D{O6=6|x.U40QFJT髲'8sIA|Bo_c"-҄#?$*Dh 6ӀkW~ t߄7"G?,?0"x:H-aH#{RȌIZd;DNY+UgrG̟ ?7^W5g6ϦE|d#kj2k^p^F@Ɓ\4F RtNq̼SM3YEy^$~T:3-ǖ>vRo%A+RBm'5MJŸf. c_i< O FDA#1 P{ ?ўm\4k>s+8U[RX-v֫iBEwec1|ʡflZ3Xiԧ$Kۭ>e`Gp '++UpMFHi}OϧZ#CBbD @(B0\VFm;fO9/6?YAu~̟r_ m*C? (=0((((((((+C͹&$ej|{$;gyCnk|ыTl(P(ōg'Ėyck aD`fw|4|' o#WѮ m?4RlecunGaX2~= iOH( N񏆴GfC}gq͆Tm`r3_4ӳ>p)QEQEQEQEQEQEQEQEQE:sgڧR0G}q+^ sg{w 7ɵ1ޝk_VukMB{@>wZAEWsQ@Q@G_YO^Yơizd1+)I$,1 3~¿H]./,R.-|C_]9FC a8»qq-4?bOG|m^yHY#=l*̢4lec2'5Os,Ia5- +@(((((~ _ 17[I!&[vB[Q!M~ajze扩]ڍoqiuX%RUр*AA,hM6:,>%ZB!+ZHXc(G)#/˳WbGF?~*֧^hޝOaYQU%]Aj}w<)ٓNK?OE_]>'t,= +L(((((((+h/q|+/$ͤIf.XoFk) $Uioo$M$)<ؕClU/wC8ƴ7#.(ӏ ( ( (?b? ڝ5]8ĭ"b-JFm:??aTz; O,2xzyfIZbgFks]kCb[[K_O >zk((((((((((S -4e_WAqJ)rg⿍/QE뜁EPEP#Mğ6}_"?|IcmcS((((((D_ m'J#c]aH!#r;n>Vޅ**pݑ9qrgLlXvGV\(1 ( G[rkMo^)T!{o^[Z:k'. 'fR>gGǥxJZdxn",elw 3`3/K4M;NO--cX$PUP 3a{=,.gBQ_{!EPEPEPEPEPEPEP/:ei3&2M"Ϩ*@v?v_ҵ~3GŁoxt=^|lyo N|sQ/x(<fO9/6?YAu~̟r_ m*3C0? (=0(((((((Ɵ^0 E)"Y!UB|(f1?*[2 #q\E$+\Ymë1 sm__Pw7N6z|Š(<(((S}ƿ rA$ڶ)";he*I\+@^l޾%?op1(\kAT[{~|9{tQE|!Q@Q@Q@Q@Q@Q@Q@Q@Q@Yo*ԯҿ,~jWO>>i](\ ( (?]m$H  &Onξs+:((((((ɶoo#++om;r~>#R?"h(((ҿ#O~jW_j/x_G~EEPEPEPEPEPo▅Sι_e9F&ٮ&acX|P@CId~+^|7+UY6P0yn3hXc&ت^givii [ZZƱ HQ*~]eV]ON +QEhQEQEQEQEQEQEQE?G~ҟ5_ ]+S75ѝK}A#u*G*aUr%8;4LS/4MJNm',{{Kr*VR 5VmN񞔰[5["LwykpK Yi_WjJ5ct2|'Iȫ dOcnW_+dQE|Q@Q@Q@Q@Q@Q@V_ >(bC[n5;U$iZG I2MaWZ+F4/sjM+c~Kq;~3 ~[ZRTgBJqR]B(K ( ( ( ( ( ( ( (?5?H?1U_Yo*ԯ2(|6|+Q^QEQE~"?|Icm#Mğ6}_?u=O !EWtQ@Q@Q@Q@Q@Q@|?wmGy_pWW6 mwtN|G~DEQEPEP_Fԯҿ#Oy_:Ə++((((g<|hPUu}' l.6r09h?,h,>KXĩ $e(;~(ݒU} X_Վz=7%𶧩kzޣ^LwR%V%ؒĒI9$jWIXТ)(+$ȼS>6 `# ,,ww{IWet1Ȅy_ko kEd KiV<+g?d߻.OVXY[i|,9-O袊Š((((((((( qNOqp%2M+]ۣD e`K*#Zڗl_hOx>8!5 ydaV{xIXXUA/i}YO TqNwY%K̈a+@l= 1"U:t>=5 V_ߴ$+t/CE1©wwHUXf&9BH [V_Aσ:;CnYY]L@lR? JB(` ( (>O];㖧Yo~dsshL A±-cqjo|1MG%uzw *hQ_4z!EPEPEPEPEPEPEPEP[i?ʿ5+ -4e_&Sϟ_@+9((o$Go?m;:Dɶ۟#+\xD(󎀢((((((mH+  &mψȚ(J>p((+5{_Wip#6sG^tQE~v}QEQEQEQE>G|S<~\jw1Zi^(ci bb{xuψ>75PN;Ue%V$q_T~n<8 6p+ s$ Tg gBO@ߍZRn%F3 05[/ Q +Dv|i"i.<Ѕ̫ 4z/49$}EW5M.[.F >dhJ:0! 0A N;lj ?s]R hx&ڬ<Ȟ7۸ݴ Cv3xK~cinѵ1"4Y#F'R o%Oi~kge碊+((+ 'J_ni)-E5e1,8 G '_A#KxgUԯ?oѵYH |iBq uSXa|8y:tQE~p}QEQEQEQEQEQEQEQEAqJ+ W~C_Ɨ(@(( &Onξேm$H 1{}Q (((((((++om;ɶoo#G.{s?#&(ҏ ( ( +4_?~okͿׅ4]Q_@QEQEQEQE~N]!n|c{o-w'O)p/Tq.I!W۾3}>F_Ƌig˻87Oa&QEwQ@Q@A^ӼU_7-mLMok5 cۂ$:mUxBĿJj7R5;U+;R .8y Wr%.~lJ (x(((((((((((((((((+4fjm5M60OADgFNJR4v&RP~A~ԿBxA6v3$K5*[VO3El'_<+(ASvZ1&f<7ĺNWnᱳީ+71 f$3 4{'#Hѭ +ɴ|ɱUL۝9ȿ&oXwk>Tc-x˟9;Nͱ27/|~y_hP\Q_0zA^AX/[?oՍh%uQ=Wt*R;5se 8EVQ@Q@wX><|~X%"YPBN]";cUv`+  7Zo J۬"Div]*!F@`Vpw~WxVJ mף>5 +((((((( W~eclRDܡKQEz QEQEm'?Gg_pW>=Kx_#ޟ,KM#V!TH*8P;V4/+8ŽWrzJW=Jx -lAtW 7ǎ?Mb(?s`ti)_ϧ4/+8ŽQ 7ǎ?`t^]Mb(?x ;9G OA)_ϧ4/+8ŽQ 7ǎ?`t^]Mb(?x ;9G OA)_ϧ4/+8ŽQ 7ǎ?`t^]Mb(?x ;9G OA)W6 mw 7ǎ?㕇>=Ex#&;McV%8I3 8b;N'BjfgS-B(<((ҿ#O~jW_j/x_G~EEPEPEPE矴Fy~u:{ Bŵݴ9a-%dtu )AFX(b ( (>Dx+,jDx+,j #(Т(((((((((((((((((+GiGcFqeIݢ^_Z%ON7 'd-EAF쒫i֭?c4I.63Pąm 6I‚N8??׼aϵݒ==#Eڈ3_GP꽣傊s4Q]7Oŏ>!}f- ܎K&fw`F8SocJta|&w4kvF۹5Ik"mVї?4FGhs}yY~ޝ i:m=#J{? H5ijaT $kR.UuʣϦH( ((?`=_wig}s?_9 l0U'o%;y,K{X~?Hm|"3Ǹ|ǽYD]N8|][@-ǫWsX[WHl2H8|E{O MMu2袊C ( (;?<1-<LUD OW D&Ð+K=oLt/RE)u VA_ͥ~45K_puY|DtY2kA9m,g~hFy YQEQEQEQEQEQEQEQE~jeclRJH?1U_e?PlWt (s((({LQ|GM>)zFqwJBe8pfO_IqZi}(4/9ydDN^^ڟ/|y̟ 7G3'/$8r2Ò]4/9ydDN^=?_xrKW2|bO'/?̟ 7GIv<ҊfO_Iq9y}.ǚQ^ ??t2|bO'/?ڟ/9%J+>1'nfO_IqSe$iEz_3'/$8rxz| x&'`@ qIMUݔ'-QE!EPEP_Fԯҿ#Oy_:Ə++(((mbrץך~m?RտZڏ#ꈟҊ(O ( ( (>Dx+,jDx+,j #(Т(((((((((((((((((*gi|=_7fEA*|K䣡 2o+9O%)i*~֕|?/YBTEpnّ{>z '/jX<)K"EUYD1) x2!WZ~|,gp C_mE@hIߍT܇f7p+yi/ z>+ ( ( w_c NlĎڳϗoY }\ŽÞ?ࢊ((?mB'. Ɛcq4p]į%e%2k~b+㺵jw&isjs%Žݬ9`Hdtu )AQXR.Ҝ9).Eq~#Y]]o؈#[ӡh-Vmel@f @+EŸɦ(QEQEQEQEQEQEAqJ+ W~C_Ɨ(@(( &Onξேm$H 1{}Q (((((((++om;ɶoo#G.{s?#&(ҏ ( ( +4_?~okͿׅ4]Q_@QEQEQE柴oŏo#.mbrTD>QE~|QEQEQE[T^è[Eq@p8#r)~g~? y4[,+YH0IܩH# 瑶"2V{X'Š(=((((((((((((((((=)Sௌk$G6I%Ibwmxm3Ĥ0TGW?4n/uY-(-U ء C[.#O_N5zyWzw=y3\]HdyXwwbK3I$IQ_cB~W|$wfX;Ëew$)+AP R2 %}K_.#8#<=c"+3$!܁-0.$qWg5#٭CÖ7p+;Š((j]]ڍ}/osiu:tt`C+A`AtPA|-Ưx)84FH Ա,ix^' R{_Wo0iׄ'>WXC#Nՙ@4bu.K/ˁMW5:|h{9Q]EPEP#ǀ|[u΋v6Ӎ 9c̤|N[b?io}I^_}mqw?)&d0+8.kik3OQ^QEQEQEQEQEQE~jeclRJH?1U_e?PlWt (s((vDɶ۟#+$Go?m;:5zGB(8 ( ( ( ( ( (  &mேmH+˿H+((J?W_F3o94uWEWgQ@Q@Q@Q@͞^hޝOaYQU%]Aj{? ~?4`y5kv,+0I0#~J~>^K(Ԁ((w.}xN QVhXeY8R RTS_߱o+|/l#( nCme#r9*A ?vOU}ǩQE|yQ@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@~ž)vz; c]>&)Dz5 d;T+?٧ڮ SfL;Fc YG$ѯS? %]/boyt1з~'C_>boyt1з~?*1= ~ K%Qh>W?[?^]_-/?.'A}? ((((|7gm;^'Sμټ>BĦ *e~]?&xNM5d>Z(@((?$G/σ-|OsYnt]GEXòe$cr`YwKZhww^FI4D rd4ܝ'kyY/m[~V|Q7EW'ЅQ@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@V_ _ҵoӯ}C߇j(_'SEJՅYAG|-<:~\i2ڰYR)hܡ`@`F{k?W֟O QZ'ޣo=_Jz4NRDܤaA]}bi ((?>|QDOj0޴-n1+6 țn*A T*i[1Ӻ?/ N񏆴GfC}gq͆Tm`r3_,3Oυ;jqZE]S[T8-u~]IgSQEsQ@Q@Q@Q@Q@Yo*ԯҿ,~jWO>>i](\ ( (?]m$H  &Onξs+:((((((ɶoo#++om;r~>#R?"h(((ҿ#O~jW_j/x_G~EEPEPEPEP{͟߅)e8u:k%nVSN#$hd!A|][@-ǫWsX[WHl2H8 V_ߴ$+t/CE1©wwHUXf&9BHԕzi*kQ_hxEPEPZ&:q=_Jb4N7aA ]MYc&C xA:ޝ Aor o+(`24o6Aa_IC?d'e4c_u3OOC(R (((((((((((((((:jwƓ}o4ZD%ӖU![?bT_h'NMjR,L #;Ų0b T=&7ZG_NLUNJo>M+Cя$O5-kſ+77n9gutʤI3A[W}^A'|?/ x[?`Յ^k & T{jR)rVdJjaEVEQ@Q@Q@/w&Ψ}hfK|f! r%x~v5z淩]:qqwu!YbY݉,I$I&O<'ៅ3Κ2zi#_F^8cvd{w֪JG}KtV俦xʜ]> ΕXhxK߬C($#yRF2cKß 5u]̆'|i17ǾLXg3w5E0THΊ(Ϣ ( ( ( ( ( ( }?i/?9xsm*}c&kiQfm T .5?Lϧ\[jC {5eoi~koC7cR(<0((O#8L{ hOƱIʬ 6KL/ |uoP!㧶ev~{O*G)p\dW:pOR?(3>((((( W~eclRDܡKQEz QEQEm'?Gg_pWH6svu~k>(Q^qQEQEQEQEQEQEM6}_]|7cmW9‘EWGQ@Q@~okRJ?Wfs~h?C(Ϡ ( ( ( ( (7a|[⟷H7og V5bINYpCI"+pTNMjxczK=5}V;}lҸHs`2H<_З6x[& !4l{{e[UG9}7$rI$ ?<4 aεq oݵD0cibO<q,g+e_`hQ_.zaEPEPEPEPEPEP^gI|!7[j4nbu19 NLt֢iI4榊[ CO.6^'ωmɾH,r?ȠbthCXRUV٣' 8EVQ@Q@Mߌ|Tt]*{_&A:¹6>_0f_T?Q}wgryxnn BHqe~M??Ŷ|%޴(T ( (?]m$H 9xN/ [}oo yWѵ`$pq}_fp?_Cw+:((((((ɶoo#+ M:Ŀ 7j6ž HqN涜`F@ϩAˉv#(Ϟ ( ( +4_?}žk-A~{kY>HߺvP YlY\sKiXgj?X袊((((((?8Mּ=j6?xX~"o/ۯ /N O]LWŨ7713D'2!d|~,9-Cy3j*֧^hޝOaYQU%]Aj}w<)((Sx]]451ZZ"^q,d+̢)%WTw~8诪x>!|p1IΫ@dqQ.FG5M_xXS@\d!1em qM,EOݗ8SZ0+Z~ڿ3}C񵍞qtF~tf\,H'rxo7]֫=XWSf{Q^qQEQEQ^UOOZKoxJHeav?1LP2.nGwKg_ *.I$ĖfbY1$^^e,:T:oiOo̳ ֓hc4HllPā#]K6@N9&(QE ( ( ?hO_u/ߴKÛ'ʗ|3moܮ͐&7ĐddWw'|=A a{khH4GWY/VR6FK&\N_]a&k~ӼSoxoP!q[JeG*8TƼP&ơc[hv^ya8D036B1VDJ#>7o  ]=2 1A)H#`d3Uf|S^=Ė 0$ɨV@m^T~55xwp4}VX̛v@ʹIl~~x#ğ &ΧjPom* )YXVRW^?~fdKUtRF}wOo<Kݻv6}c>8hpZ5iEaxC~I[:Wt6]]ĒPl@`N30=nM;3d (Š((+ ;2=G>!Ҽ50W'`` qIi۲vݢ;_?/ڷ6n*3+\i Ri m48KYpC2X同Wm,&/Uypxo ~&6in d1!UTf` W;/Ӧq7Ikc l.¶$0g>!~zȻnif@ZHwEe,, 7TTy }[}R*;{_v;Q^QEQEibgʯ `Rxw2O2'7m%wn\5\em;3¿aLI , :vH s_Ÿ;>oxz\y۰x.0@ᣗhSF5O,\Go#Mh(Ex9o9I_q95jrnc!%iJ+/B~LphBSmZdh@+!R [#>>˧x[&FKMV" \nHPYFqxVGljB[3+Š(((((kSztx{SCٵ\EtcR+\V/ȡceO-"5|OFi#66ZRd$\H uVʏR_ <-csh0,|CK [d#o]epE{x,ҦПz[ Q_yK?|?}sU55+X їjAdUY2>RӵI5 93JU# } M,LyJNIh2 ( ( (:|a2];6f7ZiŤO) F!TgڽSOo}{E~hRE !FAZ橆W#HԜ~}wB߁boyuh%#)ǯq]iH4d>a7"gA 䟓h.iwĈ5;_xzΟLgn59~ JUPm+0oVQ]Ÿ>;>o _x,y[H-NcpaOJQ擲M#?c?'6w_#J걍3UcpvU$_ _֕_[" ͵xсidě%rV#:O]:xoha>O߆4h>zM"MKx"lhY$޵(QQE ( ( \[/"pݵV3 v p&Ҍ eA !Nu~D(1oك/N|ZN g'd5ʗ3"7?r鍧'lÉ5m-H7t,#.C+DG5|Yڜλg#tTWa2jjXn ZO]\dMgWdZ"5TXDE(,ēQE}bc(k:;`!kw 7e}G Vb c$j榾ࡿgTuKGr,h;[ʌb/ݔu< B,X{j?UؕMrOc;෋t#| E -,QI+)-Bʄct`B >'x;7?f⏱O6 ߑv[6vt5Upը ]V5!?=Q\ƁEPEPEPEPExwh~flPy62۽spQM''d&՝=)yZ/%InҬypT۷)PW$|y o[Z"hWq5zj|n#=+d_N[w q# ;$) 75Z;oRu ɞC$ijYI'$MUc߿V˙Q]EPEPEPqv/o'm@) ߠ7>ţCZcLrj,_'eRup ZK~Q_==>Fbz֋w-U#;wDJKV98b^1mV4ErK6l2#|J5)iR-zӌ/Ԣ+"榊>'?nfOIާ/?J+ d;DNY?>'?n2cfOI9gާ>/?J+ d;DNY?>'?n2cfOI9gާ>/?J+ d;DNY?>'?n2cfOI9gާ>/?J+ d;DNY?>'?n2cdOcnW^y~ MNQӾx:P.-t HE!0UA :lqXtSMQ^IQEQE~r_?mտZ5?V:/_rցi$HijFK3I$s^] rrb($粊>'?nfOIwz32cfOI9gާ>/?J+ d;DNY?>'?n2cfOI9gާ>/?J+ d;DNY?>'?n2cfOI9gާ>/?J+ d;DNY?>'?n2cfOI9gާ>/=.(=((((((*1|8փ~PXL6կu P6LS+FXQhN\vd*JK> MH#_kO.IPƾ*!c? j[Phh,qe挲A jivzޙwj6_pͥk$SDUс  jvUW28j`-b6W?']K2I%υʱŻ+~V%#V,-_Gbϟloݷc7m⻮!<ȧ l| }Y_XJSğLqcekEfPN; %NF fO_IqJ4ht4+(( L>*ze|3w \[]rE4L#d2 ED|NI=/[ZߩjZū@r@Q,3=X'kz|aۉ.CN 6J _8z'=z?ƻ^ ug7CG*G2Irbp ܠd ;d%HUi7@U +mž{_'g ivk<E ]>$x0C*+o4 àx?@{yS̑EG%h5_7Ŀ]FSPQElQEQEQE~D]7b^W{LSĶ|+[Z-W7v`WwT #z+pοO?E}v7BiJ.&skSpοO?EVH7_e*?wD+z$QoQ?p/}Ju|+:<ޣøg_'["7_R_#pοO?EVHw Ԫw_>p??G;uyG(,a*=+dmObqW_7x;ZN}Hҭ!Cw1,U,I8ԯ%9.b ((((( WA_g_?G/ۛo+7gOm9owD+z$W`sZlp??G;uyG(,a*?wD+z$QoQ?p/}Ju|+:<ޣøg_'["7_R_#pοO?EVHw Ԫw_>p??G;uyG(,a*?wD+z$QoQ?p/}Ju|+:<ޣQY}U;ِ$$If<!vh5H5#vH#v:V l0    '5H5a<$$If<!vh5H5#vH#v:V l0    '5H5a<$$If<!vh5H5#vH#v:V l0    '5H5a<|$$If<!vh5'#v':V l0    '5'a<ytN9^ 2 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~_HmH nH sH tH 8`8  Normal_HmH sH tH N@N  Heading 1$@&]^a$ B*CJphN@N  Heading 2$@&]^a$ B*CJphFF  Heading 3 $@&a$ B*CJphDD  Heading 4$@&]^a$CJD@D  Heading 5$@&]^5CJ@@@  Heading 6 $@&^5CJ@@  Heading 7$@&]^CJ<@<  Heading 8$@&5CJ8 @8  Heading 9 $@&CJDA`D Default Paragraph FontRi@R 0 Table Normal4 l4a (k ( 0No List 4@4 Header !4 @4 Footer !.)@. Page NumberJY"J  Document MapM OJQJ2B22 Body TextCJDCBD Body Text Indent^CJHRH {o Balloon TextCJOJQJ^JaJPK![Content_Types].xmlj0Eжr(΢Iw},-j4 wP-t#bΙ{UTU^hd}㨫)*1P' ^W0)T9<l#$yi};~@(Hu* Dנz/0ǰ $ X3aZ,D0j~3߶b~i>3\`?/[G\!-Rk.sԻ..a濭?PK!֧6 _rels/.relsj0 }Q%v/C/}(h"O = C?hv=Ʌ%[xp{۵_Pѣ<1H0ORBdJE4b$q_6LR7`0̞O,En7Lib/SeеPK!kytheme/theme/themeManager.xml M @}w7c(EbˮCAǠҟ7՛K Y, e.|,H,lxɴIsQ}#Ր ֵ+!,^$j=GW)E+& 8PK!Ptheme/theme/theme1.xmlYOo6w toc'vuر-MniP@I}úama[إ4:lЯGRX^6؊>$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3ڗP 1Pm \\9Mؓ2aD];Yt\[x]}Wr|]g- eW )6-rCSj id DЇAΜIqbJ#x꺃 6k#ASh&ʌt(Q%p%m&]caSl=X\P1Mh9MVdDAaVB[݈fJíP|8 քAV^f Hn- "d>znNJ ة>b&2vKyϼD:,AGm\nziÙ.uχYC6OMf3or$5NHT[XF64T,ќM0E)`#5XY`פ;%1U٥m;R>QD DcpU'&LE/pm%]8firS4d 7y\`JnίI R3U~7+׸#m qBiDi*L69mY&iHE=(K&N!V.KeLDĕ{D vEꦚdeNƟe(MN9ߜR6&3(a/DUz<{ˊYȳV)9Z[4^n5!J?Q3eBoCM m<.vpIYfZY_p[=al-Y}Nc͙ŋ4vfavl'SA8|*u{-ߟ0%M07%<ҍPK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 +_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!Ptheme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] #X Yo(v*++ #&+: 9  & )V**f++++!"$%'()*!T# AA@H P0(  P0(  B S  ?RJRRyRJRKRt   # #=*urn:schemas-microsoft-com:office:smarttags PlaceName9*urn:schemas-microsoft-com:office:smarttagsplace=*urn:schemas-microsoft-com:office:smarttags PlaceType nX"Z"["]"^"`"a"c"d"## Zfmy d!j!X"Z"["]"^"`"a"c"d"##3333X"X"["["s"t"""\#e#y#########v8M<H1bZlme=MX27 W5vA APp v $k.c?*  |,#{;/<5#P[U U~^]F]^P.4aqfPРHczk#\Vs^8*@hh^h`56.hh^h`)^`)8^8`)^`()^`()pp^p`()  ^ `.@ @ ^@ `.  ^ `.88^8`56. hh^h`o(hH. ^`hH. pL^p`LhH. @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PL^P`LhH.@h 8^8`56CJ. hh^h`.hh^h`.@hh^h`)hh^h`56)^`56)8^8`56)^`()^`()pp^p`()  ^ `.@ @ ^@ `.  ^ `.hh^h`.@h8^8`56.@h56.@h8^8`56.@hh^h`56.@h8^8`56. hh^h`56o() ^`56o(. 8^8`56o(.^`o(()^`o(()pp^p`o(()  ^ `o(.@ @ ^@ `o(.  ^ `o(.hh^h`56.@hh^h`56.h hh^h`hH.88^8`.L^`L.  ^ `.  ^ `.xLx^x`L.HH^H`.^`.L^`L.@hh^h`56.@h8^8`56.@h8^8`56. hh^h`56o() ^`56o(. 8^8`56o()^`o(()^`o(()pp^p`o(()  ^ `o(.@ @ ^@ `o(.  ^ `o(.P[UF]^ $\Vs7 IK @h h^h`OJQJo(>3                  [b&A?NMv<j *U\hMEj_Uqzp r! ..}N07b508N9i(:I:Ll;;<OG<K<3,>?@v@};A^AsAYKB\CRDaECL@OP7R&S ZT4Z:Z|]dbIdk1`mMox7p}3~h~/RWF>bWpuxX{J]Y+0c d)l<XPx`0 yI^ +ew5K @6Sj3]W n[GR &*7U{o-:N.n=DO8I4 kyOb u#2Mz aM-?3^X"Z"@#@UnknownG* Times New Roman5Symbol3. * Arial5. *aTahomaA BCambria Math"1h@@@ 8> 8>!0dG"G"2QHX  ?{o2!xxOrgan and Disease PanelsColumbia Healthcare Corp.BGY0685l                   Oh+'0   0< \ h t Organ and Disease PanelsColumbia Healthcare Corp. Normal.dotmBGY06852Microsoft Office Word@@8@8@8 8՜.+,0 hp|  >G" Organ and Disease Panels Title  !"#$%&'()*+,./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnoprstuvwxyz{|}~Root Entry F`@Data -1Tableq:WordDocumentHXSummaryInformation(DocumentSummaryInformation8CompObjy  F'Microsoft Office Word 97-2003 Document MSWordDocWord.Document.89q